Lv1
60 积分 2023-05-04 加入
Immunoglobulin Light Chain Amyloidosis: 2026 Update on Diagnosis, Prognosis, and Treatment
10天前
已完结
Biting the Tail of CAR-T for Relapsed Multiple Myeloma
11天前
已完结
The consensus of genetic detection in multiple myeloma in China (2026)
11天前
已完结
A Phase 1 Study of Daratumumab, Ixazomib, and Dexamethasone in AL Amyloidosis
11天前
已完结
Graded Renal Response Criteria for Light Chain (AL) Amyloidosis
1个月前
已完结
Translocation t(11;14) Is Associated With Adverse Outcome in Patients With Newly Diagnosed AL Amyloidosis When Treated With Bortezomib-Based Regimens
1个月前
已完结
Options for Rescue Treatment of Patients with AL Amyloidosis Exposed to Upfront Daratumumab
1个月前
已完结
Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial
1个月前
已完结
Use of venetoclax in t(11;14) positive relapsed/refractory multiple myeloma: A systematic review
1个月前
已完结
Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial
1个月前
已完结
皖公网安备34019202002308
